Condition: Relapsing Multiple Sclerosis · Sponsor: University of Colorado, Denver
A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.
This description comes directly from the study's public registry record.
Enrique Alvarez, MD/PhD · 303-724-8249 · enrique.alvarez@cuanschutz.edu
Lilli Farrell, BS · lillian.farrell@cuanschutz.edu
Always discuss trial participation with your own doctor first.
| University of Colorado Anschutz Medical Campus | Aurora, Colorado, United States | Recruiting |
| Cleveland Clinic | Las Vegas, Nevada, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06529406